HDCN Abstract:  ASN Annual Meeting -- San Francisco  

Pashayan S, Sim J, Liu IA, et al.

Prevalence of Hypertension in Vitamin D Deficiency.

ASN Annual Meeting -- San Francisco
J Am Soc Nephrol (Nov) 18:629A 2007

We sought to evaluate whether an association exists between vitamin D deficiency and clinical hypertension (HTN). It has been suggested that vitamin D is a negative regulator of the renin-angiotensin system. Clinical studies have reported a possible inverse relationship between circulating vitamin D levels and blood pressure control. Our study evaluated the prevalence of hypertension across different levels of total 25-hydroxyvitamin D2/3 (D25).

Using the population database of a large integrated health plan, a retrospective, data-linkages design determined the prevalence of hypertension in subjects with known D25 levels during 1/1/04 through 12/31/06. D25 deficiency was defined as D25 <30ng/ml and further subdivided into 11-29 ng/ml and 10 ng/ml. HTN was identified by ICD-9 coding. Data on age, gender, race, and CKD class (based on GFR) were also collected.

A total of 3593 unique subjects were analyzed. HTN was present in 28.1% (812/2887) of subjects with D25 30 ng/ml, compared to 50.5% (344/681) in the 11-29 ng/mL and 60% (15/25) in the 10 ng/ml subject group (p<0.0001). Logistic regression analysis adjusting for age, gender, race, and CKD, revealed that subjects with D25 deficiency had an OR for HTN of 1.34 (95%CI 1.10-1.64).

Our study demonstrates a greater prevalence of HTN in subjects with D25 deficiency. After adjusting for CKD and other cofounders, D25 deficient patients had a greater likelihood for HTN. D25 deficiency may represent an important risk factor or comorbidity in patients with HTN.

Prevalence of HTN across Calcidiol levels
Calcidiol levels (ng/mL)HTN % (N)
1060% (15/25)*
11-2950.5% (344/681)*
3028.1% (812/2887)
* p<0.05 when compared to 30 group



The poster for this abstract is available for viewing. YOU MUST SIGN IN FIRST at the ASN Posters2View website: (you need to type in a separate username and password of your choosing). If you are not signed in, the direct link to the poster below will not work!

Once signed in, you can access the poster for this abstract directly at this link.


Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.